How do breast cancer clinical trials approach cardiovascular safety: targeted or generalized?

ABSTRACT:

Background

Different breast cancer pharmacotherapy agents cause different forms of cardiovascular toxicity. We aim to assess if breast cancer pharmacotherapy trials approach cardiovascular safety in a targeted or generalized manner when administering different agents.

Methods

We searched Embase and Medline for phase 2 and 3 breast cancer pharmacotherapy trials. We examined exclusion criterion for cardiovascular conditions and cardiovascular safety assessment through cardiovascular imaging, electrocardiogram, troponin, or natriuretic peptides. Fisher's exact test was utilized to compare reporting.

Results

Fifty breast cancer clinical trials were included in this study. Trials administering microtubule inhibitors were most likely to exclude patients with any CV conditio

SUBMITTER: Hamid A 

PROVIDER: S-EPMC10848621 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature